We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01843374
First Posted: April 30, 2013
Last Update Posted: August 17, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
MedImmune LLC
  Purpose
This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period.

Condition Intervention Phase
Unresectable Pleural or Peritoneal Malignant Mesothelioma Drug: Tremelimumab Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: 3 years. ]
    Overall survival (OS) by treatment arm


Secondary Outcome Measures:
  • OS Rate at 18 Months by Treatment Arm [ Time Frame: 18 months ]
    The percentage of patients still alive at 18 months

  • Progression-free Survival by Treatment Arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ]
    Progression-free survival will be measured from randomization to the first documentation of disease progression or death due to any cause, whichever occurs first. Progression is defined using the modified Response Evaluation Criteria in Solid Tumours (RECIST) for pleural mesothelioma or RECIST v1.1 for peritoneal mesothelioma and assessed by computed tomography (CT) or magnetic resonance imaging (MRI), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

  • Overall Response Rate by Treatment Arm [ Time Frame: Time from randomization to best response to treatment, assessed up to 3 years. ]
    Overall response rate is defined as the proportion of participants with confirmed CR or PR per the modified Response Evaluation Criteria in Solid Tumours (RECIST) for pleural mesothelioma or RECIST v1.1 for peritoneal mesothelioma and assessed by computed tomography (CT) or magnetic resonance imaging (MRI). Complete Response (CR) corresponds to disappearance of all target lesions, and Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. Overall Response (OR) = CR + PR.

  • Duration of Response by Treatment Arm [ Time Frame: Duration of response from the first documentation of objcetive response (confirmed CR or PR) to the first documented disease progression, assessed up to 14 weeks after the initial response. ]
    Duration of response will be defined as the duration from the first documentation of complete response (CR), partial response (PR) to the first documented disease progression.

  • Disease Control Rate by Treatment Arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ]
    Disease control rate (DCR) is defined as the proportion of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 12 weeks duration

  • Durable Disease Control Rate by Treatment Arm [ Time Frame: Time from randomization to disease progression or death, whichever occurs first, assessed up to 3 years. ]
    Durable disease control rate (DDCR) is defined as the percentage of participants with best response of complete response (CR), partial response (PR), or stable disease (SD) of ≥ 6 months duration

  • Number of Participants Reporting Any Adverse Event [ Time Frame: Day 1- 90 days post dose ]
    Any untoward medical occurrence in a patient or clinical investigation participants administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

  • Number of Participants Reporting Any Serious Adverse Events [ Time Frame: Day 1 to 90 days post dose ]
  • Number of Participants With Positive Anti-drug Antibodies [ Time Frame: Week 5 ]
    The immunogenicity titer is reported for samples confirmed positive for the presence of anti tremelimumab antibodies.


Enrollment: 571
Actual Study Start Date: May 17, 2013
Estimated Study Completion Date: April 2, 2018
Primary Completion Date: January 24, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tremelimumab
Tremelimumab
Drug: Tremelimumab
Tremelimumab is to be administered as an IV solution, followed by observation.
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo is to be administered as an IV solution, followed by observation.

Detailed Description:

This is a Phase 2b, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo.

Randomization will be stratified by EORTC status (low-risk vs high-risk), line of therapy (second vs third), and anatomical site (pleural vs peritoneal). This study plans to use the EORTC to stratify subjects into high or low risk groups in order to ensure balanced randomization to the different treatment groups. For subjects in whom pemetrexed was contraindicated or not tolerated or not an approved therapy (eg, peritoneal mesothelioma), prior therapy with a first-line platinum-based regimen is required. Approximately 564 subjects will be enrolled at study centers in multiple countries.

The study consists of a screening period, a treatment period, and a 90-day follow-up period.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma;
  2. Disease not amenable to curative surgery;
  3. Age 18 and over at the time of consent;
  4. ECOG Performance status 0-1;
  5. Progressed after previous receipt of 1-2 prior systemic treatments for advanced disease that included a first-line pemetrexed (or anti-folate)-based regimen in combination with platinum agent.
  6. Recovered from all toxicities associated with prior treatment, to acceptable baseline status, or a NCI CTCAE Grade of 0 or

1, except for toxicities not considered a safety risk, 7. Measurable diseaseby modified RECIST for pleural mesothelioma or RECIST v1.1 for peritoneal mesothelioma; 8. Adequate bone marrow, hepatic, and renal function determined within 14 days prior to randomization defined as: 9. Negative screening test results for human immunodeficiency virus (HIV), hepatitis A, B and C. 10. Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive authorization in the EU) obtained from the subject/legal representative prior to performing any protocol- related procedures, including screening evaluations; 11. Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of contraception after this point should be discussed with a responsible physician. 2. Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Days 1 through 90 post last dose. In addition, they must refrain from sperm donation for 90 days after the final dose of investigational product.

Exclusion Criteria:

  1. Subjects who failed more than 2 prior systemic treatment regimens for advanced malignant mesothelioma;
  2. Received any prior mAb against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1);
  3. History of chronic inflammatory or autoimmune disease with symptomatic disease within the last 3 years prior to randomization.
  4. Active, untreated central nervous system (CNS) metastasis
  5. Any serious uncontrolled medical disorder or active infection that would impair the subject's ability to receive investigational product;
  6. History of other malignancy unless the subject has been disease-free for at least 3 years;
  7. Pregnant or breast feeding at time of consent;
  8. Any condition that would prohibit the understanding or rendering of information and consent and compliance with the requirements of this protocol;
  9. Active or history of diverticulitis;
  10. Active or history of inflammatory bowel disease, irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosis or Wegener's granulomatosis;
  11. History of sarcoidosis syndrome;
  12. Currently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids.
  13. Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment;
  14. The last dose of prior chemotherapy or radiation therapy was received less than 2 weeks prior to randomization;
  15. Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of vitiligo and alopecia;
  16. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results;
  17. Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks
  18. Employees of the study site directly involved with the conduct of the study, or immediate family members of any such individuals;
  19. Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01843374


  Hide Study Locations
Locations
United States, Arizona
Research Site
Scottsdale, Arizona, United States, 85259
United States, California
Research Site
La Jolla, California, United States, 92093
Research Site
Los Angeles, California, United States, 90025
Research Site
San Francisco, California, United States, 94143
Research Site
Santa Monica, California, United States, 90404
United States, Connecticut
Research Site
New Haven, Connecticut, United States, 06520
United States, Delaware
Research Site
Newark, Delaware, United States, 19718
United States, Florida
Research Site
Tampa, Florida, United States, 33612
United States, Georgia
Research Site
Augusta, Georgia, United States, 30912
United States, Illinois
Research Site
Chicago, Illinois, United States, 60637
Research Site
Peoria, Illinois, United States, 61615
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21201
Research Site
Baltimore, Maryland, United States, 21231
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States, 55445
United States, New York
Research Site
New York, New York, United States, 10065
Research Site
Rochester, New York, United States, 14642
United States, North Carolina
Research Site
Durham, North Carolina, United States, 27710
United States, Ohio
Research Site
Canton, Ohio, United States, 44710
United States, Pennsylvania
Research Site
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
Research Site
Dallas, Texas, United States, 75390
Research Site
Houston, Texas, United States, 77030
Australia
Research Site
Adelaide, Australia, 5000
Research Site
Auchenflower, Australia, 4066
Research Site
Box Hill, Australia, 3128
Research Site
Chermside, Australia, 4032
Research Site
East Bentleigh, Australia, 3165
Research Site
Gosford, Australia, 2250
Research Site
Heidelberg, Australia, 3084
Research Site
Nedlands, Australia, 6009
Research Site
Saint Leonards, Australia, 2065
Research Site
Waratah, Australia, 2298
Belgium
Research Site
Antwerp, Belgium, 2650
Research Site
Gent, Belgium, 9000
Research Site
Leuven, Belgium, 3000
Canada, Ontario
Research Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Research Site
Sainte Foy, Quebec, Canada, G1V 4G5
Denmark
Research Site
Copenhagen, Denmark, 2100
France
Research Site
Caen Cedex, France, 14000
Research Site
Le Mans Cedex, France, 72037
Research Site
Lille Cedex, France, 59037
Research Site
Nice Cedex, France, 06189
Research Site
Rennes Cedex 9, France, 35033
Research Site
Toulouse, France, 31059
Research Site
Villejuif, France, 94805
Germany
Research Site
Berlin, Germany, 13125
Research Site
Esslingen a.N., Germany, 73730
Research Site
Freiburg, Germany, 79106
Research Site
Gauting, Germany, 82131
Research Site
Grosshansdorf, Germany, 22927
Research Site
Hamburg, Germany, 21075
Research Site
Hemer, Germany, 58675
Research Site
Karlsruhe, Germany, 76137
Research Site
Lubeck, Germany, 23538
Research Site
Löwenstein, Germany, 74245
Hungary
Research Site
Matrahaza, Hungary, 3233
Research Site
Törökbálint, Hungary, 2045
Israel
Research Site
Beer-Sheva, Israel, 84101
Italy
Research Site
Alessandria, Italy, 15100
Research Site
Aviano, Italy, 33081
Research Site
Bergamo, Italy, 24125
Research Site
Bologna, Italy, 40138
Research Site
Candiolo, Italy, 10060
Research Site
Genova, Italy, 16132
Research Site
Meldola, Italy, 47014
Research Site
Milano, Italy, 20133
Research Site
Orbassano, Italy, 10043
Research Site
Padova, Italy, 35128
Research Site
Rozzano, Italy, 20089
Research Site
Siena, Italy, 53100
Korea, Republic of
Research Site
Jeonnam, Korea, Republic of, 58128
Research Site
Seoul, Korea, Republic of, 03722
Research Site
Seoul, Korea, Republic of, 05505
Research Site
Seoul, Korea, Republic of, 135-710
Netherlands
Research Site
Breda, Netherlands, 4818 CK
Research Site
Eindhoven, Netherlands, 5623EJ
Research Site
Rotterdam, Netherlands, 3015 CE
Poland
Research Site
Gdansk, Poland, 80-952
Research Site
Poznan, Poland, 60-693
Research Site
Szczecin, Poland, 70-891
Research Site
Warszawa, Poland, 02-781
Romania
Research Site
Craiova, Romania, 200385
Russian Federation
Research Site
Moscow, Russian Federation, 115478
Research Site
Nizhny Novgorod, Russian Federation, 603006
Research Site
Saint-Petersburg, Russian Federation, 197022
South Africa
Research Site
Kraaifontein, South Africa, 7570
Research Site
Pretoria, South Africa, 0081
Research Site
Pretoria, South Africa, 0181
Spain
Research Site
Barcelona, Spain, 08035
Research Site
Madrid, Spain, 28040
Research Site
Sabadell (Barcelona), Spain, 08208
Research Site
San Sebastian, Spain, 20014
Research Site
Sevilla, Spain, 41013
Sweden
Research Site
Linkoping, Sweden, 58185
Research Site
Lund, Sweden, 22185
Research Site
Umea, Sweden, SE90185
United Kingdom
Research Site
Leeds, United Kingdom, LS9 7TF
Research Site
Leicester, United Kingdom, LE1 5WW
Research Site
London, United Kingdom, EC1A 7BE
Research Site
London, United Kingdom, SE1 9RT
Research Site
Maidstone, United Kingdom, ME16 9QQ
Research Site
Manchester, United Kingdom, M23 9LT
Research Site
Plymouth, United Kingdom, PL6 8DH
Research Site
Southampton, United Kingdom, SO16 6YD
Research Site
Wirral, United Kingdom, CH63 4JY
Sponsors and Collaborators
MedImmune LLC
  More Information

Additional Information:
Responsible Party: MedImmune LLC
ClinicalTrials.gov Identifier: NCT01843374     History of Changes
Other Study ID Numbers: D4880C00003
First Submitted: April 22, 2013
First Posted: April 30, 2013
Results First Submitted: April 10, 2017
Results First Posted: August 17, 2017
Last Update Posted: August 17, 2017
Last Verified: August 2017

Keywords provided by MedImmune LLC:
tremelimumab
pleural, peritoneal
malignant mesothelioma
CTLA-4

Additional relevant MeSH terms:
Mesothelioma
Lung Neoplasms
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Tremelimumab
Antibodies, Monoclonal
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs